The effect of quinidine, a strong P-glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol

The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol

(2014) Khanh Bui et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain

(2014) William D. Chey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Why Clinical Modulation of Efflux Transport at the Human Blood–Brain Barrier Is Unlikely: The ITC Evidence-Based Position

(2013) J C Kalvass et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation

(2013) Lynn Webster et al.   PAIN

The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults

(2011) Kelly Posner et al.   AMERICAN JOURNAL OF PSYCHIATRY

Novel opioid antagonists for opioid-induced bowel dysfunction

(2011) Laura Diego et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain

(2010) a. k. tuteja et al.   NEUROGASTROENTEROLOGY AND MOTILITY

The Prevalence, Severity, and Impact of Opioid-Induced Bowel Dysfunction: Results of a US and European Patient Survey (PROBE 1)

(2008) Timothy J. Bell et al.   PAIN MEDICINE

Meeting the Challenges of Opioid-Induced Constipation in Chronic Pain Management – A Novel Approach

(2008) Karen Reimer et al.   PHARMACOLOGY